9 results about "Immunologic specificity" patented technology

Myocilin-binding agents including antibodies and antigen binding fragments thereof and fusion proteins that immunospecifically bind the coiled-coil domain of myocilin but do not bind to misfolded myocilin are provided herein. The disclosed antibodies and antigen binding fragments and fusion proteins are useful for the detection and extraction of natively folded myocilin from a sample.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

Provided herein are pharmaceutical compositions comprising antibodies that immunospecifically bind to KIT, a receptor tyrosine kinase, and uses thereof. Also provided are kits and methods for producing such pharmaceutical compositions. KIT (or c-Kit) is a type III receptor tyrosine kinase encoded by the c-kit gene. KIT comprises five extracellular immunoglobulin (ig)-like domains, a single transmembrane region, an inhibitory cytoplasmic juxtamembrane domain, and a split cytoplasmic kinase domain separated by a kinase insert segment.

The present invention relates to a method of detecting liver cancer in a mammalian subject by detecting an antibody in a test sample comprising a bodily fluid from the mammalian subject, wherein the antibody is an autoantibody immunologically specific for a tumour marker protein selected from the group consisting of MMP9, AIF1, EpCAM and CDKN1B, which method comprises contacting the test sample with a tumour marker antigen selected from the group consisting of MMP9, AIF1, EpCAM and CDKN1B and determining the presence or absence of complexes of the tumour marker antigen bound to autoantibodies present in the test sample where the presence of said complexes is indicative of the presence of liver cancer. Also included within the invention are corresponding methods of diagnosing and treating liver cancer in a mammalian subject, corresponding methods of predicting response to an anti-liver cancer treatment, a corresponding method of detecting an antibody in a test sample comprising a bodily fluid from a mammalian subject and kits suitable for performing methods of the invention.

Disclosed herein are fully human antibody molecules that immunospecifically bind to human IL-5. The antibody molecules can bind to human IL-5 with an equilibrium affinity constant (KD) of at least about 40 pM as determined by surface plasmon resonance.

The present invention provides methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands. The present invention provides methods of treating cancer using a molecule having an antigen binding fragment that immunospecifically binds to BTN1A1 or a BTN1A1 ligand, such as an anti-BTN1A1 antibody or an anti-BTN1A1 ligand antibody. The present invention also provides a BTN1A1 ligand, such as a galectin-1 (galectin-1), a galectin-9 (galectin-9), a neuropilin-2 (Neuropilin-2), and a B-and T-lymphocyte attenuating protein, for example, a BTN1A1 ligand, for example, a Galectin-1 (Galectin-1), a Galectin-9 (Galectin-9), a Galectin-9 (Galectin-9), a Galectin-2 (

The present invention provides methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands. The present invention provides methods of treating cancer using a molecule having an antigen binding fragment that immunospecifically binds to BTN1A1 or a BTN1A1 ligand, such as an anti-BTN1A1 antibody or an anti-BTN1A1 ligand antibody. The present invention also provides a BTN1A1 ligand, such as a galectin-1 (galectin-1), a galectin-9 (galectin-9), a neuropilin-2 (Neuropilin-2), and a B-and T-lymphocyte attenuating protein, for example, a BTN1A1 ligand, for example, a Galectin-1 (Galectin-1), a Galectin-9 (Galectin-9), a Galectin-9 (Galectin-9), a Galectin-2 (

Provided herein are molecules or antibodies that immunospecifically binds to a surface unit or a transmembrane unit of a rabies virus glycoprotein (RABV-G). The molecules and antibodies typically including an antigen binding region of an antibody having six complementarity determining regions (CDRs). Also provided are antibody-conjugates (e.g., antibody-drug conjugates) and fusion proteins can include an antigen binding domain and a heterologous amino acid sequence. For example, chimeric antigen receptor (CAR) polypeptides including the provided antigen binding domains are also provided. In some forms, the CAR includes an extracellular antigen binding region, a spacer region, a transmembrane region, and intracellular signaling region. In some forms, the CAR includes a co-stimulatory domain. Nucleic acids encoding the molecules, antibodies, and fusions proteins such as CAR, and cells expressing the same are also provided. Pharmaceutical compositions including the provided compositions and methods of use thereof are also provided.